OVERVIEW OF THE PHARMACEUTICAL MARKET IN JAPAN
Espicom projects that the Japanese pharmaceutical market will experience a slight CAGR contraction in dollar terms between 2012 and 2017. Japan will be the second largest pharmaceutical market in the Asia Pacific region, having been overtaken by China in 2016. Japan has a growing elderly population and in 2017 it is expected to be the largest in percentage terms in the Asia Pacific region, at over a quarter of the population. This will put enormous pressure on the government’s healthcare budget. Japan will also rank as the country with the second largest total health expenditure and third highest per capita health spending in the Asia Pacific region in 2017, due to its large population of over 65 years old that creates a high demand for pharmaceuticals. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-japan.html
The government and MHLW have sought to increase generic drugs usage to around 30% in 2012. From the experience of other countries, this would imply a sales value level of roughly 10%, should the volume target be reached. The Japan Generic Medicines Association estimates that generic drugs sales accounted for just under 10% of pharmaceutical sales by value and nearly a quarter of pharmaceutical sales by volume in 2011. There were a number of competitive strategies completed in the second half of 2011: Teva acquired Kowa’s 50% stake in the Teva-Kowa Pharma JV; Teva completed its acquisition of Taiyo; and Fujifilm and Dr Reddy's Laboratories signed a MoU to establish a JV.
Takeda is the largest Japanese pharmaceutical manufacturer in terms of sales, and has been by a considerable margin for some time. Other leading domestic producers include Astellas, Daiichi Sankyo and Eisai. Over the past five years, the fastest growing pharmaceutical companies have been Mitsubishi Tanabe Pharma, Dainippon Sumitomo Pharma, Kyowa Hakko Kirin Company, Shionogi & Co Ltd. and Otsuka. The leading foreign pharmaceutical companies in terms of sales in Japan are Pfizer, Roche and Novartis. A number of multinational companies are actively seeking to expand their operations in Japan, notably Pfizer, GlaxoSmithKline, Novartis and Bristol-Myers Squibb.
PROVIDING STRATEGIC MARKET ANALYSIS EVERY MONTH
Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles
EXECUTIVE SUMMARY. 1
Snapshot: Strategic Espicom Analysis..2
Snapshot: Key Data Projections..3
MACROENVIRONMENT .... 4
Infant Deaths 8
Life Expectancy at Birth. 8
Leading Causes of Mortality9
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS... 10
REGULATORY AFFAIRS... 15
Periodic Safety Reporting .18
LABELLING & PACKAGING19
PRICING & REIMBURSEMENT... 20
REIMBURSEMENT ... 20
National Health Insurance Drug Price List20
DISTRIBUTION CHANNELS.. 21
Trade Association 21
DRUG RETAILING 22
Selected Pharmacy Chains23
MARKET ANALYSIS 24
For more information kindly visit :
The Pharmaceutical Market : Japan
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
The Pharmaceutical Market : Japan